Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Children's Hospitals and Clinics of Minnesota |
---|---|
Information provided by: | Children's Hospitals and Clinics of Minnesota |
ClinicalTrials.gov Identifier: | NCT00751647 |
The purpose of this project is to determine the short-term effects of a customized Core Strengthening and Respiratory Exercise Program (CSREP) on children with cystic fibrosis (CF) between the ages of 10 and 21 who are receiving outpatient care at Children's Hospitals and Clinics of Minnesota. The CSREP, which will be provided by a physical therapist and a physical therapist assistant, consists of specific breathing techniques and core strengthening exercises, designed to improve rib cage mobility, pulmonary function, aerobic capacity, posture, and core strength. Currently the CF population at Children's receives physical therapy on an inpatient basis only.
The overall goal of this program is to prove the viability of an outpatient exercise program for this population. Specific aims include:
Condition | Intervention | Phase |
---|---|---|
Cystic Fibrosis |
Other: Physical Therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Supportive Care, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | Cystic Fibrosis Core Strengthening and Respiratory Exercise Program (CSREP) |
Estimated Enrollment: | 10 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A1
Population receiving the CF specific outpatient PT services.
|
Other: Physical Therapy
Treatment
|
Study Design: Phase II clinical trial.
Objective: To determine whether a customized physical therapy exercise intervention titled Core Strengthening and Respiratory Exercise Program (CSREP) clinically improves the following outcome measures for children between the ages of 10 and 21 with cystic fibrosis: pulmonary function, aerobic capacity, rib cage mobility, posture, and core strength, thus warranting more extensive study and development.
Background: Previous research conducted in pediatric populations has focused on the effects of aerobic training, anaerobic training, and strengthening of the extremities on the health of children with cystic fibrosis. However, the disease process of cystic fibrosis secondarily causes impairments in the musculoskeletal and nervous systems. No intervention study aimed at positively impacting these systems has been done to date with children with cystic fibrosis.
Methods: A 6-month CSREP will be customized to meet the specific needs of each participant. During Part I of the program participants will attend weekly CSREP treatments for 4 to 6 weeks; in Part II they will attend monthly CSREP treatments over a five-month period. Each session will last for 45-60 minutes. During these treatments, participants will be given instruction on a daily home exercise program and will receive hands on physical therapy interventions. Handouts with pictures and how-to instructions for assigned exercises will be provided. Participants will be given calendars to track completion of home exercises and level of compliance. During Part II, a researcher will call participants every week in order to encourage compliance with the home exercise program and to provide clarification as needed. All participants will continue to receive regular medical care as well as PT treatments.
A respiratory therapist will perform the pulmonary function tests, a respiratory therapist along with an exercise physiologist will perform the VO2max testing, and a physical therapist will perform the physical therapy evaluation, including assessment of rib cage mobility, core strength, and posture.
Another physical therapist as well as a physical therapist assistant will provide the physical therapy treatments, instruct the participants in their home program, and make the weekly phone calls to all participants.
An experience survey will be designed to evaluate both satisfaction on a scale of 1 to 10 and self scoring of outcome measures including: respiratory function, cough strength, activity tolerance, posture, and strength on a three point Likert scale of: 1) Got worse; 2) Stayed the same; and 3) Got better. Additionally, the survey will include a question on the likelihood of continuing with the home program after the study has ended. The survey will be administered at 6 months upon completion of the program.
Relevance: The results of this inquiry as to the viability of the CSREP will prove relevant to the above-mentioned patient outcomes within the cystic fibrosis population. The customized CSREP protocol will provide a non-pharmacological outpatient treatment option that can be completed on an outpatient basis, independently, in the patient's home.
Ages Eligible for Study: | 10 Years to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion Criteria:
Contact: Mahrya A Johnson | 612-813-6384 | mahrya.johnson@childrensmn.org |
Contact: Julie Christiansen | 612-813-6376 | julie.christiansen@childrensmn.org |
United States, Minnesota | |
Children's Hospitals and Clinics of Minnesota | Recruiting |
Minneapolis, Minnesota, United States, 55404 | |
Contact: Laurie Blumberg-Romero, MA 612-813-7628 laurie.blumberg-romero@childrensmn.org | |
Contact: Mahrya A Johnson, BA, CCRP 612-813-6384 mahrya.johnson@childrensmn.org | |
Sub-Investigator: John McNamara, MD | |
Principal Investigator: Katie Fenlon | |
Sub-Investigator: Julie Christiansen | |
Sub-Investigator: Lorre Thompson |
Principal Investigator: | Katie Fenlon, PT | Children's Hospitals and Clinics of MN |
Responsible Party: | Children's Hospitals and Clinics of Minnesota ( Laurie Blumberg-Romero/Research Administrator ) |
Study ID Numbers: | 0807-068 |
Study First Received: | September 11, 2008 |
Last Updated: | March 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00751647 History of Changes |
Health Authority: | United States: Institutional Review Board |
CF |
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases |
Pathologic Processes Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases |